ASGE Annual GI Advanced Practice Provider Course (Virtual) - Clinical Case-Based Learning (Day Two) | April 2023-NordICC Trial and CRC Screening

Pdf Summary

This document discusses the NordICC Trial and its implications for colorectal cancer (CRC) screening. It highlights different screening tests including the fecal immunochemical test (FIT), multitarget stool DNA tests (MT-sDNA), and colonoscopy. The article focuses on the findings of the NordICC Trial, which aimed to measure the benefits of colonoscopy in population screening. The trial found that colonoscopy reduced the risk of CRC by 18% over 10 years, but the reduction in CRC death was not significant. The document also discusses the media response to the trial, emphasizing the importance of understanding and communicating the expert analysis of the study. It provides information on what healthcare providers and patients should know based on the trial's results. For healthcare providers, it highlights the operator-dependent nature of colonoscopy and the importance of follow-up and surveillance colonoscopies. For patients, it stresses the importance of colonoscopy in detecting and removing precancerous polyps and early cancers, as well as the need for follow-up if FIT or MT-sDNA tests are positive. The document concludes by providing resources from the American Society for Gastrointestinal Endoscopy (ASGE) for further education on APP topics related to CRC screening.

Asset Subtitle

Joseph Vicari, MD, MBA, FASGE

Keywords

NordICC Trial

colorectal cancer screening

fecal immunochemical test

FIT

multitarget stool DNA tests

MT-sDNA

colonoscopy

benefits of colonoscopy

population screening

media response to NordICC Trial